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Abstract 
Background  
The cellular response of malignant tumors to hypoxia is diverse. Several important 
endogenous metabolic markers are upregulated under hypoxic conditions. We 
examined the staining patterns and co-expression of HIF-1α, CAIX, LDH-5, GLUT-
1, MCT1 and MCT4 with the exogenous hypoxic cell marker pimonidazole and the 
association of marker expression with clinicopathological characteristics. 
Methods  
20 biopsies of advanced head and neck carcinomas were immunohistochemically 
stained and analyzed. All patients were given the hypoxia marker pimonidazole 
intravenously 2 h prior to biopsy taking. The tumor area positive for each marker, the 
colocalization of the different markers and the distribution of the markers in relation 
to the blood vessels were assessed by semiautomatic quantitative analysis. 
Results  
MCT1 staining was present in hypoxic (pimonidazole stained) as well as non-hypoxic 
areas in almost equal amounts. MCT1 expression showed a significant overall 
correlation (r=0.75, p<0.001) and strong spatial relationship with CAIX. LDH-5 
showed the strongest correlation with pimonidazole (r=0.66, p=0.002). MCT4 and 
GLUT-1 demonstrated a typical diffusion-limited hypoxic pattern and showed a high 
degree of colocalization. Both MCT4 and CAIX showed a higher expression in the 
primary tumor in node positive patients (p=0.09 both).  
Conclusions  
Colocalization and staining patterns of metabolic and hypoxia-related proteins 
provides valuable additional information over single protein analyses and can 
improve the understanding of their functions and environmental influences. 
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Background 
Malignant tumors often exhibit an altered metabolism compared to normal tissues. 
This phenomenon can be explained by several underlying mechanisms. First of all, 
the genetic changes related to a high proliferation rate, as observed in many tumors, 
lead to an increased metabolism[1]. Another important reason for a changed 
metabolism is the adaptation of tumor cells to the microenvironment. Due to rapid 
tumor growth, hypoxic areas are frequently encountered. Under circumstances of 
severe hypoxia, cells are forced to use anaerobic glycolysis as their primary energy 
source, the Pasteur effect[2]. Normal cells convert to oxidative phosphorylation when 
oxygen levels are restored. In contrast, tumor cells can use aerobic glycolysis even in 
the presence of sufficient amounts of oxygen. This is called the Warburg effect, a 
manifestation of a modification of the tumor cell metabolism[3]. Due to a high level 
of aerobic glycolysis, in many tumor cells, glucose consumption is substantially 
higher than in normal cells.[4,5] 
The consequence of the high rate of glycolysis in malignant cells is the production of 
large amounts of lactic acid. An interesting observation made by Sonveaux et al. is 
the preference of tumor cells for lactic acid over glucose as the primary energy 
source.[6] This creates the perfect conditions for a symbiosis between anaerobic 
glycolytic cells and aerobic tumor cells [6] or aerobic stromal cells, as described in 
colorectal carcinomas.[7] 
Recently, monocarboxylate transporters (MCT’s) have been discovered to play an 
important role in this symbiosis. These transporters facilitate the uptake and excretion 
of monocarboxylates, like lactate and pyruvate, and act as monocarboxylate-proton 
symporters[8]. MCT4 is a low-affinity / high capacity lactate transporter, which is 
abundantly present in highly glycolytic muscle cells. It is one of the many target 
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genes of hypoxia-inducible factor 1 (HIF-1)[9]. MCT1 is a high-affinity, low capacity 
monocarboxylate transporter, found in normal tissues like the intestinal epithelium 
(executing an important role in organic acid absorption), the blood brain barrier, red 
blood cells and skeletal muscle cells. Its expression seems to be regulated by multiple 
signaling pathways, microenvironmental parameters, changes in substrate 
concentration and pH[8]. Other important proteins related to the metabolism of tumor 
cells are glucose transporter-1 (GLUT-1), the main transporter involved in glucose 
influx, and lactate dehydrogenase-5 (LDH-5), responsible for the conversion of 
pyruvate into lactate. Like MCT4, these proteins are upregulated under hypoxic 
conditions by HIF-1[10]. Another main target for HIF-1 is carbonic anhydrase IX 
(CAIX), a hypoxia-related protein involved in pH regulation[11], that shows weak 
correlations with the exogenous hypoxia marker pimonidazole[12, 13]. The advantage 
of the use of these proteins as endogenous immunohistochemical markers is that no 
prior infusion of markers is necessary and therefore archived material can be used to 
assess the metabolic and, possibly, the hypoxic status of the tumor. However, up until 
now no endogenous marker has been identified that correlates strongly with 
pimonidazole[14]. In this study, we describe and quantify the expression patterns and 
colocalization of several important hypoxia-related and metabolic markers in biopsies 
of head and neck tumors and in particular the association with pimonidazole as the 
reference exogenous hypoxic marker[15]. 
 
Methods 
Samples 
The study was approved by the local ethics committee. 20 biopsies from 18 head and 
neck tumors were included in the analysis; from two tumors two biopsies were 
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available. All patients received pimonidazole (1-((2-hydroxy-3-piperidinyl)propyl)-2-
nitroimidazole hydrochloride, Hypoxyprobe-1; Natural Pharmacia International, 
Belmont, MA) intravenously (500mg/m2) two hours before biopsy taking. 
Pimonidazole is a bioreductive chemical probe that forms protein adducts in viable 
hypoxic cells. Biopsies were snap frozen in liquid nitrogen and stored until further 
processing. The samples were cut in sections of 5µm and stained by 
immunofluorescence for pimonidazole, HIF-1α, CAIX, GLUT-1, LDH-5, MCT1, 
MCT4 and vessels in different combinations of 3 markers per tissue section. 
 
Immunohistochemistry 
For immunohistochemical processing, the sections were fixed for 10 minutes in 
acetone and rehydrated in PBS 0.1 mol/L (pH 7.4) (Klinipath, Duiven, The 
Netherlands). Between all consecutive steps of the staining procedure the sections 
were rinsed thrice for 5 minutes in PBS. 
For detection of pimonidazole, sections were incubated with rabbit-anti-pimo 
antibody (J.A. Raleigh, Department of Radiation Oncology and Toxicology, 
University of North Carolina, Chapel Hill, North Carolina, USA) diluted 1:1000 in 
primary antibody diluent (PAD, Abcam, Cambridge, UK) for 30 minutes at 37°C. The 
second incubation step was with donkey-anti-rabbit Alexa488 (Molecular Probes, 
Leiden, The Netherlands) diluted 1:600 in PBS. Staining for vessels was done by 
incubation with the mouse antibody PAL-E (Euro Diagnostica, Arnhem, The 
Netherlands) diluted 1:10 in PAD, followed by incubation with chicken-anti-mouse 
Alexa647 (Molecular Probes) for 60 min at 37°C diluted 1:100 in PBS. 
The same secondary antibody (in a different tissue section) was used to detect CAIX, 
after incubation with mouse-anti-CAIX antibody (E. Oosterwijk, Department of 
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Urology, University Medical Center, Nijmegen), diluted 1:25 in PAD for 30 min at 
37°C. 
For detection of MCT1, sections were incubated with goat-anti-MCT1 (Santa 
Cruz)[7], 1:100 in PAD, overnight at 4°C. The next day the secondary antibody was 
added: donkey-anti-goatCy3 (Jackson Immuno Research Laboratories Inc., West 
Grove, PA, USA) 1:600 in PBS, 30 min at 37°C. 
Staining for MCT4 was done by incubation with rabbit-anti-MCT4 (Santa Cruz)[16], 
1:100 in PAD, overnight at 4°C. The secondary antibody was either goat-anti-
rabbitFabCy3 (1:600 in PBS) or donkey-anti-rabbitAlexa488 (1:600 in PBS) 
depending on the combination of markers stained in that tissue section.  
Sections were incubated with rabbit-anti-GLUT-1 (Neomarkers, Fremont, CA, USA.), 
diluted 1:100 in PAD for 30 min at 37°C, followed by donkey-anti-rabbitAlexa488, 
1:600 in PBS for 30 min at 37°C for detection of GLUT-1. 
Staining for HIF-1α was done by incubation with rabbit-anti-HIF-1α (Santa Cruz), 
diluted 1:50 in PAD overnight at 4°C, followed by goat-anti-rabbitCy3 (Jackson 
Immuno Research Laboratories Inc.), 1:600 in PBS for 30 min at 37°C. In the same 
section, all nuclei were stained with Hoechst (Sigma, Zwijndrecht), 0.33 µg/ml, in 
PBS for 5 min at room temperature. 
Finally, for detection of LDH-5 sections were incubated with sheep-anti-LDH-5 
(Abcam), diluted 1:100 in PAD overnight at 4°C. The next day, incubation with 
donkey-anti-sheepCy3 (Jackson Immuno Research Laboratories Inc.), 1:600 in PBS 
for 30 min at 37°C, completed the staining. 
All sections were mounted in fluorostab (ProGen Biotechnik GmbH, Heidelberg, 
Germany). 
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Image acquisition and analysis 
The tissue sections were scanned using a digital image processing system consisting 
of a high-resolution 12-bit CCD camera (Micromax, Roper Scientific Inc., Trenton, 
NJ, USA) on a fluorescence microscope (Axioskop, Zeiss, Göttingen, Germany) and a 
computer-controlled motorised stepping stage. Image processing was done using 
IPLab software (Scanalytics Inc., Fairfax, VA, USA) on a Macintosh computer[17]. 
Each tissue section was sequentially scanned for the three signals at 100x 
magnification with a resolution of 2.6 µm / pixel. The resulting composite grey scale 
images were converted to binary images for further analysis. Thresholds for the 
fluorescent signals were interactively set above the background for each individual 
marker. The composite grey scale images were superimposed into one pseudocolored 
image for visual evaluation. 
 
Guided by an H&E stained consecutive section, the tumor area of each section was 
delineated. This area was subsequently used as a mask in further analysis from which 
non-tumor tissue, large necrotic areas and artefacts were excluded. The marker 
fractions were defined as the tumor area positive for the marker, divided by the total 
tumor area. With this method, an automated quantitative analysis of the percentage of 
positively stained tumor tissue can be obtained. To determine the colocalization of the 
various markers with pimonidazole, the relative area positive within and outside the 
pimonidazole stained area was calculated.  Similar analyses were done to assess the 
colocalization between MCT1, MCT4, GLUT-1 and CAIX. 
The spatial distribution of the markers in relation to the blood vessels was measured 
by calculating the relative area positive in six zones around the closest vessels with a 
width of 50 µm each (0-50µm, 50-100µm, 100-150µm, 150-200µm, 200-250µm 
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and>250µm)[17]. As the absolute fractions differ greatly, normalisation of fractions 
was performed for clear comparison of distributions. Quantitative analysis of the HIF-
1α staining was not possible because of the low signal-to-background ratio in many 
HIF-1α-positive areas. All sections were visually scored by two observers and 
divided in two groups; high and low HIF-1α expression based on the intensity and the 
estimated fraction of HIF-1α positive cells. Differences between the observers were 
resolved at the microscope.  
 
 
Statistics 
Statistical analyses were done with Prism software package for Macintosh. The 
relationships between metabolic parameters (as continuous variables) were tested 
using the Spearman rank correlation coefficient or the Pearson correlation coefficient 
as appropriate. Differences in colocalization were analyzed with a Mann-Whitney 
test. To test the association of the markers with categorical tumor characteristics (T-
stage, N-stage and histopathological grade) either the Mann-Whitney test or Fisher’s 
exact test (after dichotomization of the variables) was used. 
 
Results 
20 biopsies of 18 patients with histologically confirmed advanced stage squamous cell 
carcinoma of the head and neck were included in this study. Tumor characteristics are 
shown in Table 1. 
 
Correlation between metabolic markers and tumor characteristics 
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A trend to a higher expression of both MCT4 and CAIX in node positive patients was 
observed (p = 0.09 both) (Figure 1). After dichotomization of the variables MCT4 
expression was significantly higher in node positive patients (p = 0.01). HIF-1α only 
showed a trend towards higher expression in node positive patients (p = 0.06), 
although HIF-1α expression was only found in one node negative tumor. In this 
biopsy the HIF-1α expression as well as the pimonidazole staining was found in well-
differentiated areas around keratinization. T4 tumors showed a significantly lower 
pimonidazole staining (p = 0.02) and CAIX expression (p = 0.03) than T2 or T3 
tumors. This inverse trend was found for MCT1 and MCT4 as well (p = 0.09 and p = 
0.08 respectively). No correlations were found between any of the markers and 
differentiation grade. 
 
Staining patterns 
Examples of staining of all markers are shown in Figure 2. Pimonidazole fraction 
ranged from 0 - 34% (median 7%) and different hypoxic patterns were observed. 
Some tumors showed a typical ribbon-like pattern, others a more patchy pattern[18]. 
(Figure 2a/b) Extensive cytoplasmic LDH-5 expression was seen in most of the 
tumors (fraction range 17 - 91%, median 37%, figure 2c), with more intense staining 
in hypoxic areas. 
Membranous CAIX expression closely followed the hypoxic pattern in some tumors, 
in others CAIX staining showed less spatial correlation with pimonidazole. The 
fraction ranged from 0 - 43% (median 4.7%) (Figure 2a,b,d). 
MCT 1 showed a clear membranous staining pattern with substantial variation in 
intensity and extent; in some sections large MCT1 positive areas were seen, in other 
sections almost no MCT1 was present (fraction range 0.1 - 64%, median 14%). 
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MCT1 staining was not only observed adjacent to hypoxic areas, but also within 
hypoxic areas (Figure 2e).  
MCT 4 showed a more diffuse staining pattern, with fractions varying from 0.6 - 49% 
(median 14%) and with more staining at increasing distance from the vessels. GLUT-
1 had a comparable staining pattern to MCT4 (fraction range 3 - 43%, median 18%): 
diffuse staining throughout the tissue section, with more staining at increasing 
distance from the vessels. (Figure 2f/g) 
Apparent localised nuclear HIF-1α staining was present in 15 out of 20 biopsies, 
mostly in and around hypoxic areas (Figure 2h) with large variation in intensity. In 
some tissue sections membranous or cytoplasmatic staining was present as well, but 
only nuclear staining was taken into account. 
 
Correlations between markers 
To get a global impression of the associations between the six markers overall 
correlations were calculated, irrespective of the geographical distribution. (Figure 3) 
The strongest correlation with pimonidazole was observed for LDH-5 fraction (r = 
0.66, p = 0.002). CAIX showed significant correlations with MCT1, MCT4 and 
GLUT-1.  
The expression of the endogenous markers was compared between biopsies with a 
high and low HIF-1α expression. (Figure 3) Overall, biopsies with a high HIF-1α 
expression demonstrated a significantly higher CAIX fraction. Remarkably, two 
biopsies clearly showed HIF-1α expression, but very low fractions of CAIX, GLUT-1 
and MCT4. In one of the biopsies pimonidazole staining was associated with well-
differentiated keratinizing areas as described by Janssen et al.[19], the other biopsy 
showed no pimonidazole staining at all. Overall, mean pimonidazole staining was 
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equal in biopsies with high and low HIF-1α expression. A schematic representation of 
the associations between the markers is shown in Figure 3. 
 
Colocalization of metabolic and hypoxic markers 
The results of the quantitative analysis of the colocalization of the various markers are 
shown in Figure 4. MCT4 expression was significantly higher in hypoxic areas than 
in non-hypoxic areas (p = 0.001) and also clearly correlated to CAIX expression. 
GLUT-1 expression and MCT4 expression showed an even stronger amount of 
colocalization with approximately six times higher GLUT-1 expression in MCT4 
positive areas. 
MCT1 was present in well-oxygenated areas, but unexpectedly showed considerable 
expression in hypoxic areas as well (no significant difference, p = 0.11). Additionally, 
MCT1 expression was significantly correlated with CAIX expression (p < 0.001). 
Pimonidazole stained areas exhibited, beside MCT4, a significantly higher expression 
of CAIX and LDH-5 compared to pimonidazole negative areas. 
Although colocalization with HIF-1α expression could not be analyzed in the same 
manner as the other markers, it was observed that pimonidazole-related CAIX areas 
showed more intense HIF-1α expression than CAIX areas far from pimonidazole 
positive hypoxic areas (Figure 2 i-j). 
 
Relationship of markers with vasculature 
Chronic hypoxia is an important feature of malignant tumors, marked by a tissue 
oxygen gradient with lower oxygen tensions farther from the blood vessels. The 
expression of the endogenous markers in relation to the vessels, with pimonidazole as 
a reference hypoxic marker, can provide valuable information about their usefulness 
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as a marker of chronic hypoxia. To assess the expression of the markers in relation to 
the vessels, fractions were calculated at different distances from the most nearby 
vessel in steps of 50 µm. In general, hypoxic fraction and LDH-5 staining increased at 
larger distances from the vessels. GLUT-1 and MCT4 were present in variable 
fractions in the proximity of vessels, but the expression increased about two to four-
fold at > 150 µm from the vessels. All except four tumors exhibited this “chronic 
hypoxic pattern”. These remaining four showed no pimonidazole staining. Two 
examples of the distribution of the markers in tumors with pimonidazole (chronic 
hypoxic pattern) and without pimonidazole staining (non-hypoxic pattern) are shown 
in Figure 5. In one tumor (5a and b) with a large hypoxic fraction (20%) 
pimonidazole binding increases steeply with distance from the vessels. GLUT-1, 
MCT4 and LDH-5 follow this pattern but less steep, with a plateau reached between 
150-200 µm. MCT1 expression increases until 150-200 µm and decreases at larger 
distances. In the second tumor (Figure 5c and d) all metabolic markers were strongly 
expressed without any relationship with the vessels and, in the absence of 
pimonidazole, not depending on hypoxia. Low HIF-1α and CAIX expression was 
present in this tumor. 
MCT1 expression clearly showed a different pattern compared to the other markers; 
in most tumors the MCT1 fraction increased slightly till 100 µm from the vessels and 
remained constant or modestly decreased again at larger distances. However, in the 
four tumors without hypoxia, MCT1 expression was present close to the vessels and 
decreased farther from the vessels. 
 
 
Discussion 
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Hypoxia is an important feature of advanced head and neck tumors, with a negative 
influence on prognosis[12, 20]. Evaluation of cellular responses to hypoxia can be of 
clinical relevance in a prognostic and predictive way and possibly for treatment 
adaptation. Until now no endogenous marker has been found that strongly and 
consistently correlates with hypoxia, so different kind of analyses as presented here 
are crucial to elucidate the role of the various proteins and the response of tumor cells 
to a hypoxic microenvironment.  
Although a global analysis of the overall expression of a certain protein allows easy 
comparison between biopsies and between different studies, it is a huge simplification 
of the true heterogeneous situation in a tumor biopsy. Therefore, to gain more insight 
in the spatial relationship between the metabolic markers and the oxygenation status 
in the tumor, we additionally assessed the expression of the proteins within and 
outside pimonidazole stained areas and the relation to the vessels. With this analysis 
more markers show an evident relationship with pimonidazole than with a global 
correlation analysis (Figure 4). 
 
Of the endogenous hypoxia-related markers that we examined, LDH-5 has the 
strongest relationship with pimonidazole. LDH-5 is one of the target enzymes of HIF-
1 and has been described to have a strong association with HIF-1α expression in 
tumor tissue sections [21, 22]. The high expression of LDH-5 in hypoxic areas is as 
expected; it is one of the key enzymes in the glycolysis, the primary energy source in 
the absence of oxygen. The reason for a considerable expression of LDH-5 outside 
hypoxic areas could be the high rate of aerobe glycolysis (the Warburg effect) as 
often observed in malignant tumors[4], although alternative explanations are possible, 
as pyruvate can originate from other pathways as well[23]. It should be noted that due 
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to the similarity between LDH-5 and the other LDH isoforms, there is a possibility of 
some cross-reactivity of the antibody. 
 
CAIX is previously described to correlate weakly with pimonidazole binding[13, 24, 
25]. Despite the weak overall correlation, CAIX fraction was significantly higher in 
the hypoxic (pimonidazole positive) areas. This emphasizes the strong association of 
this protein with hypoxia that could not be found by a simple correlation analysis. 
Interestingly, although all the endogenous markers, with the exception of MCT1, are 
regulated by HIF-1[9, 10], the staining patterns and colocalization differ. An 
interesting observation is the strong resemblance of the HIF-1α and CAIX staining 
pattern (intermediate hypoxic areas). This typical pattern circumferences the 
pimonidazole stained area with a partial overlap (Fig. 2i). The colocalization of CAIX 
with HIF-1α is far from perfect, but more concordant than that of GLUT-1, MCT4 
and LDH-5 with HIF-1α. The strong relationship of CAIX with HIF-1 is known, with 
CAIX expression tightly controlled by HIF-1[26]. In this context, an interesting 
observation is the higher level of HIF-1α expression in hypoxia-related CAIX areas 
than in CAIX areas separate from hypoxic (pimonidazole stained) areas (Figure 2i/j). 
A possible explanation of these findings could be the increased transcription of HIF-
1α without stabilization in the intermediate hypoxic areas (areas with CAIX 
expression without HIF-1α staining) and stabilization of HIF-1α in severe hypoxic 
areas (areas overlapping and adjacent to pimonidazole with CAIX and HIF-1α 
staining)[27]. It could also indicate the transient presence of acute hypoxic areas, 
which are reoxygenated before pimonidazole administration. It was shown in SiHa 
(human cervical squamous cell carcinoma) tumors that up to 20% of the tumor cells 
were intermittently hypoxic over an 8-hour period[28]. This explanation is less likely 
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as CAIX upregulation requires a longer period of hypoxia[29]. A third explanation 
could be the induction of HIF-1α and consequent activation of CAIX through a 
hypoxia-independent mechanism without stabilization of HIF-1α under these 
conditions. An acidic tumor microenvironment can influence HIF-1α and CAIX 
expression as well[29,30]. In any case, there is little evidence for a HIF-1 independent 
CAIX activating mechanism[26].  
 
Most markers showed a range of co-expression, but a very strong spatial relationship 
was found between GLUT-1 and MCT4 (Figure 4h). These showed a comparable, 
typical expression increasing at larger distances from the vessels, with a two- to four-
fold increase of the fraction at 150-200 µm. This pattern and agreement reflects their 
interrelated role in the glycolytic pathway under hypoxic conditions, GLUT-1 for 
glucose import and MCT4 for lactate export. LDH-5, one of the intermediary 
enzymes in this pathway, shows a similar pattern, but was not stained in the same 
section as MCT4 or GLUT-1, so the amount of colocalization could not be calculated.  
Although a small series, a positive correlation between MCT4 and N-stage was found. 
Overexpression of MCT4 in malignancies has been described in colorectal cancer[31] 
and cervical carcinomas[32]. Except for a trend towards shorter overall survival with 
MCT4 positive adenosquamous carcinomas of the cervix, no correlations with 
clinicopathological data have been found before. These findings indicate that MCT4 
is a potential marker for the aggressiveness of a tumor. 
MCT1 expression in > 5% of the tumor area was present in 14 of the 20 biopsies. 
MCT1 expression in tumors has been described in lung cancer[33], brain tumors[34] 
and cervical cancer[32]. However, in the colonic epithelium, Lambert et al. found a 
decline in expression associated with transition to malignancy[35]. In our study, 
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MCT1 expression was present in oxic as well as hypoxic areas, in contrast to the 
observation made by Sonveaux et al. in biopsies of lung carcinomas[6]. It is important 
to note that in our study a different antibody was used of which some aspecificity 
formally can not be excluded, although other studies show good results with this 
antibody as well[7, 36]. As the fraction MCT1 even increased at larger distance from 
the vessels, it seems likely that MCT1, beside MCT4, plays a role in lactate export in 
hypoxic areas. It is reasonable to assume that in tumor cells, like in red blood cells, 
depending on the substrate concentrations and pH, MCT1 functions as either a lactate 
importer or assists MCT4 in lactate export[37]. Either way, MCT1 has already shown 
some potential as a therapeutic target in vitro. Inhibition of MCT1 by lonidamine 
induced a strong decrease in intracellular pH and loss of viability of the tumor 
cells[34]. The MCT1 inhibitor α-cyano-4-hydroxycinnamate blocks lactate-fueled 
respiration in tumor cells and induces tumor growth retardation in a mouse model[6]. 
Of interest is the strong correlation and colocalization of MCT1 with CAIX (Figure 3 
and 4e), affirming an important role in pH regulation as described in melanoma and 
neuroblastoma[34, 38]. 
In conclusion, metabolic markers show a strong but irregular relation with hypoxia 
with obvious correlations between markers, emphasizing the complex metabolic 
regulatory system with a strong environmental (hypoxia, pH) influence. Co-
expression of markers provides additional information over single marker fractions. 
MCT4 and GLUT-1 show a typical “diffusion-limited hypoxic” pattern with a strong 
colocalization indicating activation by similar stimuli. The positive correlation with 
N-stage makes MCT4 a potential marker for tumor aggressiveness, but its exact value 
still has to be established. MCT1 overexpression is present in the majority of the 
advanced head and neck carcinomas in our series, in non-hypoxic as well as hypoxic 
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areas. The strong colocalization with CAIX suggests an important role in pH 
regulation.  
 
Conclusion 
Endogenous metabolic and hypoxia-related markers can be of great importance as 
prognostic and predictive markers and are potential therapeutic targets. As the various 
markers respond differently to hypoxia and other environmental factors, a 
combination of these markers could be used to predict treatment outcome and select 
the appropriate patients for new targeted therapies. 
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Figures 
 
Figure 1 MCT4 and CAIX expression according to nodal stage 
A significantly higher expression of MCT4 (p=0.04, a) and CAIX (p=0.05, b) was 
found in node-positive tumours. One tumor without nodal metastasis had a high 
CAIX expression of 17%. Interestingly, no HIF-1α expression was found in this 
tumor. 
 
Figure 2 Immunofluorescent staining pattern of metabolic and hypoxic markers 
(a and b) Fluorescent microscopic images of two head and neck carcinomas with 
different pimonidazole (green) and CAIX (blue) staining patterns.  
(c – h) Examples of staining of the various markers. (c) LDH-5 (red), pimonidazole 
(green) and vessels (white). (d) Perinecrotic pimonidazole (green) and CAIX (red) 
staining, N = Necrosis. (e) MCT1 (red), pimonidazole (green) and vessels (white), 
note the co-staining of MCT1 with pimonidazole. (f and g) Membranous GLUT-1 (f) 
and MCT4 (g) (both red) staining in relation to the vessels (white). (h) Nuclear HIF-
1α (red) expression in relation to pimoniazole (green) staining. (i and j) Fluorescent 
microscopic images showing intense HIF-1α (red) staining in a pimonidazole-related 
(green) CAIX (blue) area and almost absent HIF-1α staining in another CAIX area in 
the same tissue section. 
 
Figure 3 Correlations between the endogenous markers and pimonidazole  
A schematic representation has been added; solid lines represent a significant 
correlation, dashed lines a trend (p-value between 0.05-0.1). Percentages in the 
second table are mean values. 
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Figure 4 Colocalization of the various markers 
(a-d) CAIX, LDH-5 and MCT4 show a significantly higher expression in 
pimonidazole stained areas, MCT1 expression is not significantly different. (e and f) 
Expression of MCT1 and MCT4 in CAIX negative and positive areas, both are 
significantly higher in areas expressing CAIX. (g and h) Increased expression of 
MCT1 and GLUT in MCT4 positive areas.  
 
Figure 5 Marker expression in different zones around the vessels  
Zone analysis in a biopsy with a large hypoxic fraction (upper panels) and a tumor 
with no pimonidazole staining (lower panels). Pimonidazole staining increases 
steadily at larger distances from the vessels (a). The increase of GLUT, MCT4 and 
LDH-5 expression is less steep with a plateau reached between 150-200 µm (b). 
MCT1 expression increases until 150-200 µm, a slight decrease is noted at larger 
distances (a). In the tumour with no pimonidazole staining, a decrease in MCT1 
expression (c) and no increase of GLUT, MCT4 and LDH-5 expression (d) is 
observed at larger distances from the vessels. 
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Table 1 Tumour site, stage and grade 
Characteristics Number 
Tumour site   
Larynx 7 
Hypopharynx 4 
Oropharynx 5 
Oral cavity 2 
T stage   
T2 3 
T3 6 
T4 9 
N stage   
N0 6 
N+ 12 
Histopathological grade   
Moderately differentiated 14 
Poorly differentiated 4 
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